Podcasts
What is your health worth? PROMs, EQ-5D & economic evaluation
9 June 2026
Grace Hampson is joined by David Mott, Associate Director at OHE, as well as Hannah Hussain, an Economist at OHE, both part of OHE’s Measuring and Valuing Outcomes…
AI and the future of health economics
2 June 2026
Grace Hampson is joined by Tim Reason, co-founder and managing director of Estima Scientific, and Dalia Dawoud, Research Principal in HTA Policy and Strategy at Cytel to dive into AI’s incredible potential –…
Should HTA look beyond the healthcare system?
26 May 2026
Grace Hampson is joined by Chris Skedgel, a Director at OHE, to dig into one of health economics’ most contested methodological debates: what are health systems trying to achieve through…
Can joint clinical assessment speed up access to medicines?
19 May 2026
Grace Hampson is joined by Patrick Hopkinson, founder of PHTA Consulting and global market access expert, and Matthias Hofer, Senior Principal Economist at OHE, to take…
When antibiotics stop working: the hidden crisis in plain sight
12 May 2026
Grace Hampson is joined by Lotte Steuten, Deputy CEO of the Office of Health Economics and David McKinney, Co-founder of ARMoR, to dig into the market failures surrounding the AMR crisis and…
Most Favored Nation pricing: what it means for policy, patients and pharma
5 May 2026
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?
Welcome to A Dose of Economics
29 April 2026
When demand for healthcare is growing but budgets are finite, the “how” and “why” of decision-making matters.